We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$39.6M
Cap. Flow %
0.67%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 97.06%
2 Financials 1.87%
3 Miscellaneous 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
126
DELISTED
Agile Therapeutics
AGRX
$2.23M 0.04%
+600
New +$3.44M
ARWR icon
127
Arrowhead Research
ARWR
$9.98B
$1.96M 0.03%
+68,100
New +$2.75M
FLNA
128
CALL
Filana Therapeutics
FLNA
$33.6M
$1.53M 0.03%
+250,000
New +$1.66M
APLS
129
DELISTED
Apellis Pharmaceuticals
APLS
$1.35M 0.02%
+50,485
New +$1.79M
BMY.RT
130
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.33M 0.02%
350,000
– –
ELDN icon
131
Eledon Pharmaceuticals
ELDN
$220M
$1.24M 0.02%
176,851
– –
STRO icon
132
Sutro Biopharma
STRO
$275M
$1.07M 0.02%
10,480
– –
PPBT
133
Purple Biotech
PPBT
$2.8M
$1.06M 0.02%
+1,731
New +$2.12M
FLXN
134
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.05M 0.02%
133,000
– –
CRIS icon
135
Curis
CRIS
$2.74M
$956K 0.02%
3,396
– –
LRMR icon
136
Larimar Therapeutics
LRMR
$406M
$852K 0.01%
92,211
+23,794
+35% +$313K
XENT
137
DELISTED
Intersect ENT, Inc
XENT
$812K 0.01%
+68,553
New +$1.52M
MBIO icon
138
Mustang Bio
MBIO
$3.82M
$675K 0.01%
336
– –
PTGX icon
139
Protagonist Therapeutics
PTGX
$9.28B
$472K 0.01%
66,909
-124,300
-65% -$931K
ATXS
140
DELISTED
Astria Therapeutics
ATXS
$184K ﹤0.01%
+7,400
New +$229K
OTIC
141
DELISTED
Otonomy, Inc.
OTIC
$142K ﹤0.01%
71,994
-278,706
-79% -$859K
BLRX
142
BioLineRX
BLRX
$12.2M
$92K ﹤0.01%
1,731
– –
ABT icon
143
Abbott
ABT
$177B
– –
-715,100
Closed -$62.1M
ACAD icon
144
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-96,143
Closed -$4.11M
AMRN
145
Amarin Corp
AMRN
$294M
– –
-12,480
Closed -$5.35M
AVTR icon
146
Avantor
AVTR
$10.4B
– –
-1,012,800
Closed -$18.4M
AZN icon
147
AstraZeneca
AZN
$251B
– –
-34,800
Closed -$3.47M
DHR icon
148
Danaher
DHR
$147B
– –
-720,679
Closed -$98.1M
ELV icon
149
Elevance Health
ELV
$90.6B
– –
-106,600
Closed -$32.2M
INCY icon
150
Incyte
INCY
$24.7B
– –
-59,500
Closed -$5.2M
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.